CD5 and diffuse large B-cell lymphoma: The same was seen with COO, forwhich most CD5-positive cases were non-GCB, a finding consistent with theliterature.1 This subgroupof patients has poorer outcomes, with a 5-year overall survival of 34% compared with50% in CD5-negative DLBCL.